HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

BACKGROUND: Although clear cell renal cell carcinoma (ccRCC) is well known as a highly immunogenic tumor, only a small subset of patients could benefit from current immunotherapy, which might be due to the heterogeneity of immune microenvironment in ccRCC. So, it is meaningful to explore novel immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qiang-Hua, Li, Kai-Wen, Chen, Xu, He, Hai-Xia, Peng, Sheng-Meng, Peng, Shi-Rong, Wang, Qiong, Li, Ze-An, Tao, Yi-Ran, Cai, Wen-Li, Liu, Ran-Yi, Huang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057441/
https://www.ncbi.nlm.nih.gov/pubmed/31959726
http://dx.doi.org/10.1136/jitc-2019-000157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057441/
https://www.ncbi.nlm.nih.gov/pubmed/31959726
http://dx.doi.org/10.1136/jitc-2019-000157

Ejemplares similares